Silexion Therapeutics
SLXN
7 hedge funds and large institutions have $46.7K invested in Silexion Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
33% more capital invested
Capital invested by funds: $35.2K → $46.7K (+$11.5K)
17% more funds holding
Funds holding: 6 → 7 (+1)
0.05% more ownership
Funds ownership: 0.06% → 0.11% (+0.05%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$20.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.05K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
-$1.82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $26.8K | +$15.3K | +872 | +71% |
|
|
TSS
2
Two Sigma Securities
New York
| $14.9K | +$20.4K | +1,166 | New |
|
|
MA
3
Montag & Associates
Atlanta,
Georgia
| $3.84K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $662 | -$2.05K | -117 | -69% |
|
|
PK
5
Pflug Koory
Omaha,
Nebraska
| $426 | – | – | – |
|
6
Jones Financial Companies
Des Peres,
Missouri
| $32 | – | – | – |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $26 | -$1.82K | -104 | -98% |
|
SLXN Hedge Fund Activity: Q1 2026 in Review
7 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q1 2026, worth a combined $46.7K — up 33% from $35.2K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SLXN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $20.4K. The largest seller was UBS Group, cutting an estimated $2.05K.
- 7 institutional investors held Silexion Therapeutics (SLXN) as of Q1 2026, up from 6 in Q4 2025.
- Funds reported $46.7K of Silexion Therapeutics stock for Q1 2026, up 33% quarter-over-quarter.
- 1 fund opened new Silexion Therapeutics positions in Q1 2026 and 0 closed out, a net change of +1 holder.
- The largest Silexion Therapeutics buyer in Q1 2026 was Two Sigma Securities, an estimated $20.4K added.
- The largest Silexion Therapeutics seller in Q1 2026 was UBS Group, an estimated $2.05K sold.
Based on aggregated 13F filings for Q1 2026.